Animal models of urinary bladder cancer and their application to novel drug discovery

Expert Opinion on Drug Discovery

Volumn 9, Issue 5, 2014, Pages 485-503

  Oliveira, Paula A ^a   Arantes Rodrigues, Regina ^a   Vasconcelos Nóbrega, Carmen ^b  

^a UNIVERSITY OF TRÁS OS MONTES AND ALTO DOURO   (Portugal)

^b POLYTECHNIC INSTITUTE OF VISEU   (Portugal)

Author keywords

Chemical carcinogenesis; Drugs; Rodents; Tumor; Urinary bladder

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; ATORVASTATIN; CELECOXIB; CIGLITAZONE; CIMETIDINE; CORTISONE ACETATE; COTRIMOXAZOLE; DOXORUBICIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GENISTEIN; IMIQUIMOD; INDOMETACIN; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NIMESULIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OLTIPRAZ; PACLITAXEL; PIROXICAM; RAPAMYCIN; RAPAMYCIN DERIVATIVE; RC 180; RESVERATROL; SULINDAC SULFONE; TAMOXIFEN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VAPREOTIDE;

BLADDER CANCER; CANCER MODEL; CANCER TRANSPLANTATION; CARCINOGENESIS; CHEMICAL CARCINOGENESIS; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EXPERIMENTAL ANIMAL; EXPERIMENTAL MODEL; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; PRIORITY JOURNAL; REVIEW; RODENT; TUMOR XENOGRAFT; ANIMAL; DISEASE MODEL; DRUG DEVELOPMENT; URINARY BLADDER NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; URINARY BLADDER NEOPLASMS;

EID: 84899095759     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.902930     Document Type: Review

References (172)

1. Sexton WJ, Wiegand LR, Correa JJ, et al. Bladder cancer: a review of nonmuscle invasive disease. Cancer Contr 2010;17:256-68
2. Colombel M, Soloway M, Akaza H, et al. Epidemiology, staging, grading, and risk stratification of bladder cancer. Eur Urol 2008;7(Supp l7):618-26
3. Wu X, Ros MM, Gu J, et al. Epidemiology and genetic susceptibility to bladder cancer. BJU Int 2008;102:1207-15
4. Lopez-Beltran A, Sauter G, Gasser T, et al. Infiltrating urothelial carcinoma World Health Organization classification of tumours pathology and genetics of tumours of the urinary system and male genital system. IARC Press, Lyon, France; 2004. p. 93-109
5. Lorenzo-Gómez MF, Padilla-Fernández B, Arcila-Piedrahita A, et al. Metastatic urothelial cancer of the bladder cancer presented for the first time in its final stage: case report and literature review. J Palliative Care Med 2012;2:122
6. Chu H, Wang M, Zhang Z. Bladder cancer epidemiology and genetic susceptibility. J Biomed Res 2013;27:170-8
7. Mostafa MH, Sheweita SA, O'Connor PJ. Relationship between schistosomiasis and bladder cancer. Clin Microbiol Rev 1999;12:97-111 (Pubitemid 29055955)
8. Wirth M, Plattner VE, Gabor F. Strategies to improve drug delivery in bladder cancer therapy. Expert Opin Drug Deliv 2009;6:727-44
9. Eiján AM, Lodillinsky C, Sandes EO. Animal models for basic and preclinical research in bladder cancer. In: Canda A, editor, Bladder cancer - from basic science to robotic surgery. InTech, Croatia; 2012. p. 383-404; ISBN: 978-953-307- 839-7
10. Mitra AP, Datar RH, Cote RJ. Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. J Clin Oncol 2006;24:5552-64 (Pubitemid 46631336)
11. Stein JP, Skinner DG. Radical cystectomy for invasive bladder cancer: long-term results of a standard procedure. World J Urol 2006;3:296-304 (Pubitemid 44143761)
12. Yang X, Flaig TW. Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application. Int Braz J Urol 2010;36:273-82
13. Smith K, Fennelly JA, Neal DE, et al. Characterization and quantitation of the epidermal growth factor receptor in invasive and superficial bladder tumors. Cancer Res 1989;49:5810-15 (Pubitemid 19274129)
14. Tanaka MF, Sonpavde G. Diagnosis and management of urothelial carcinoma of the bladder. Postgrad Med 2011;123:43-55
15. Lamm DL. Complications of bacillus Calmette-Guerin immunotherapy. Urol Clin North Am 1992;19:565-72
16. van der Meijden AP, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 2003;44:429-34 (Pubitemid 37185667)
17. Sylvester RJ, Oosterlinck W, van der Meijden AP. A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials. J Urol 2004;171:2186-90 (Pubitemid 38625431)
18. Ismaili N, Amzerin M, Flechon A. Chemotherapy in advanced bladder cancer: current status and future. J Hematol Oncol 2011;4:35-45
19. Loehrer PJS, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1992;10:1066-73
20. Gabriel U, Bolenz C, Michel MS. Experimental models for therapeutic studies of transitional cell carcinoma. Anticancer Res 2007;27:3163-71 (Pubitemid 47610487)
21. Vargo-Gogola T, Rosen JM. Modelling breast cancer: one size does not fit all. Nat Rev Cancer 2007;7:659-72 (Pubitemid 47327411)
22. Varley CL, Southgate J. Organotypic and 3D reconstructed cultures of the human bladder and urinary tract. Methods Mol Biol 2011;695:197-211
23. Wessler S. Introduction: what is a model? In: Animal models of thrombosis and hemorrhagic disease. National Institutes of Health, Bethesda; 1976. p. 11-16
24. Reis LO, Pereira TC, Favaro WJ, et al. Experimental animal model and RNA interference: a promising association for bladder cancer research. World J Urol 2009;27:353-61
25. Xiao Z, McCallum TJ, Brown KM, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer 1999;81:638-46 (Pubitemid 29458859)
26. Oliveira PA, Colaco A, De la Cruz PLF, et al. Experimental bladder carcinogenesis-rodent models. Exp Oncol 2006;28:2-11
27. Arentsen HC, Hendricksen K, Oosterwijk E, et al. Experimental rat bladder urothelial cell carcinoma models. World J Urol 2009;27:313-17
28. Raghavan D, Debruyne F, Herr H, et al. Experimental models of bladder cancer: a critical review. In: Liss AR, editor, Developments in bladder cancer. Experimental models of bladder cancer: a critical review. New York; 1986. p. 171-208
29. Gutiérrez JB, Salsamendi AL. Fundamientos de cie?ncia toxicológica. Madrid, Diaz de Santos; 2001. p. 155-77
30. Okajima E, Hiramatsu T, Hirao K, et al. Urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl) nitrosamine in dogs. Cancer Res 1981;41:1958-66 (Pubitemid 11114604)
31. Armstrong EC, Bonser GM. Epithelial tumours of the urinary bladder in mice induced by 2-acetylamino-fluorine. J Pathol 1944;6:506-12
32. Lijinsky W. Species differences in nitrosamine carcinogenesis. J Cancer Res Clin Oncol 1984;108:46-55 (Pubitemid 14095223)
33. Steinberg GD, Brendler CB, Ichikawa T, et al. Characterization of an N-methyl- N-nitrosourea-induced autochthonous rat bladder cancer model. Cancer Res 1990;50:6668-74 (Pubitemid 20348798)
34. Oliveira PA, Palmeira C, Lourenc?o L, et al. Evaluation of DNA content in preneoplastic changes of mouse urinary bladder induced by N-butyl-N-(4- hydroxybutyl) nitrosamine. J Exp Clin Cancer Res 2005;24:207-14
35. Ito N, Shirai T, Fukushima S, et al. Dose-response study of urinary bladder carcinogenesis in rats by N-butyl-N-(4- hydroxybutyl)nitrosamine. J Cancer Res Clin Oncol 1984;108:169-73 (Pubitemid 14095243)
36. Cohen SM, Friedell GH. Neoplasms of the urinary system. In: Foster HL, Small JD, Fox JG, editors, The mouse in biomedical research. Neoplasms of the urinary system. Academic Press, New York; 1982. p. 439-63
37. Oliveira PA, Palmeira C, Colaco A, et al. DNA content analysis, expression of Ki- 67 and p53 in rat urothelial lesions induced by N-butyl-N-(4-hydroxybutyl) nitrosamine and treated with mitomycin C and Bacillus Calmette-Guerin. Anticancer Res 2006;26:2995-3004 (Pubitemid 44161792)
38. Arantes-Rodrigues R, Colac?o A, Pinto-Leite R, et al. In vitro and in vivo experimental models as tools to investigate the efficacy of antineoplastic drugs on urinary bladder cancer. Anticancer Res 2013;33:1273-96
39. Gil da Costa RM, Oliveira PA, Bastos MM, et al. Ptaquiloside-induced early-stage urothelial lesions show increased cell proliferation and intact beta-catenin and e-cadherin expression. Environ Toxicol 2012,doi:10.1002/tox. 21803
40. Cohen SM. Comparative pathology of proliferative lesions of the urinary bladder. Toxicol Pathol 2002;30:663-71 (Pubitemid 36015307)
41. Oliveira PA, Colac?o A, de la Cruz PLF, et al. Rat and mouse urothelial carcinogenesis. Exp Pathol Health Sci 2008;2:23-8
42. Epstein JI, Amin MB, Reuter VR, et al. The World Health Organization/ International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998;22:1435-48 (Pubitemid 28550639)
43. Boorman GA, Wood M, Fukushima S. Tumours of the urinary bladder. IARC Sci Publ 1994;111:383-406
44. Dinney CP, Fishbeck R, Singh RK, et al. Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice. J Urol 1995;154:1532-8
45. Steele VE, Lubet RA. The use of animal models for cancer chemoprevention drug development. Semin Oncol 2010;37:327-38
46. Rosenbert MP, Bortner D. Why transgenic and knockout animal models should be used (for drug efficacy studies in cancer). Cancer Metastasis Rev 1998;17:295-9 (Pubitemid 29210169)
47. Thomas H, Balkwill F. Assessing new anti-tumour agents and strategies in oncogene transfenic mice. Cancer Metastasis Rev 1995;14:91-5
48. Martínez-Torrecuadrada J, Cifuentes G, López-Serra P, et al. Targeting the extracellular domain of fibroblast growth factor receptor 3 with human singlechain Fv antibodies inhibits bladder carcinoma cell line proliferation. Clin Cancer Res 2005;11:6280-90 (Pubitemid 41262959)
49. Martínez-Torrecuadrada JL, Cheung LH, López-Serra P, et al. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis. Mol Cancer Ther 2008;7:862-73 (Pubitemid 351551039)
50. Cook N, Jodrell DI, Tuveson DA. Predictive in vivo animal models and translation to clinical trials. Drug Discov Today 2012;17:253-60
51. Khleif NS, Curt GA. Animal models in developmental therapeutics. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, editors, Holland-frei cancer medicine. 5th edition. BC Decker, Hamilton; 2000
52. Gunther JH, Jurczok A, Wulf T, et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res 1999;59:2834-7 (Pubitemid 29283119)
53. Ibrahiem EH, Nigam VN, Brailovsky CA, et al. Orthotopic implantation of primary N-4-(5-Nitro-2- furyl)-2-thiazolyl] formamide-induced bladder cancer in bladder submucosa: an animal model for bladder cancer study. Cancer Res 1983;43:617-22 (Pubitemid 13193857)
54. Oliveira PA, Pires MJ, Nóbrega C, et al. Technical report: technique of bladder catheterization in female mice and rats for intravesical instillation in models of bladder cancer. Scand J Lab Anim Sci 2009;36:5-9
55. Grubbs CJ, Lubet RA, Koki AT, et al. Celecoxib inhibits N-butyl-N-(4- hydroxybutyl)-nitrosamine-induced urinary bladder cancers in male B6D2F1 mice and female Fischer-344 rats. Cancer Res 2000;60:5599-602
56. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. Br J Cancer 1970;24:746-54
57. Ruggeri BA, Camp F, Miknyoczki S. Animal models of disease: Pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem Pharmacol 2014;87:150-61
58. Palmeira C, Oliveira PA, Lameiras C, et al. Biological similarities between murine chemical-induced and natural human bladder carcinogenesis. Oncol Lett 2010;1:373-7
59. Arantes-Rodrigues R, Pinto-Leite R, da Costa RG, et al. Cytogenetic characterization of an N-butyl-N-(4- hydroxybutyl) nitrosamine-induced mouse papillary urothelial carcinoma. Tumour Biol 2013;34:2691-6
60. Lu Y, Liu P, Wen W, et al. Cross-species comparison of orthologous gene expression in human bladder cancer and carcinogen-induced rodent models. Am J Transl Res 2010;3:8-27
61. Yanagisawa T, Suzuki T, Kudoh T, et al. Effect of intravesical Bacillus Calmette- Guerin on N-butyl-N-(4-hydroxybutyl)- nitrosamine induced urinary bladder carcinogenesis in rats. Nihon Hinyokika Gakkai Zasshi 1994;85:945-52 (Pubitemid 24216972)
62. Tanaka S, Kudoh S, Mollik AU, et al. Histological study on intravesical instillation of Bacillus Calmette Guerin (BCG) and adriamycin for BBN induced bladder tumor in rats. Nihon Hinyokika Gakkai Zasshi 1992;83:368-73
63. Steinberg GD, Brendler CB, Squire RA, et al. Experimental intravesical therapy for superficial transitional cell carcinoma in a rat bladder tumor model. J Urol 1991;145:647-53
64. Ohtani M, Fukushima S, Ito N, et al. Effects of intravesical instillation of antitumor drugs on the induction of preneoplastic bladder lesions in rats. Cancer Chemother Pharmacol 1983;11(Suppl):S64-6 (Pubitemid 14177303)
65. Miyazaki J, Nishiyama H, Yano I, et al. The therapeutic effects of R8-liposome- BCG-CWS on BBN-induced rat urinary bladder carcinoma. Anticancer Res 2011;31:2065-71
66. Piazza GA, Thompson WJ, Pamukcu R, et al. Exisulind, a novel proapoptotic drug, inhibits rat urinary bladder tumorigenesis. Cancer Res 2001;61:3961-8 (Pubitemid 32720958)
67. Lubet RA, Clapper ML, McCormick DL, et al. Chemopreventive efficacy of Targretin in rodent models of urinary bladder, colon/intestine, head and neck and mammary cancers. Oncol Rep 2012;27:1400-6
68. Zhang G, Zeng X, Li C, et al. Inhibition of urinary bladder carcinogenesis by aqueous extract of sclerotia of Polyporus umbellatus fries and polyporus polysaccharide. Am J Chin Med 2011;39:135-44
69. Lubet RA, Steele VE, Juliana MM, et al. Screening agents for preventive efficacy in a bladder cancer model: study design, end points, and gefitinib and naproxen efficacy. J Urol 2010;183:1598-603
70. Prasain JK, Jones K, Moore R, et al. Effect of cranberry juice concentrate on chemically-induced urinary bladder cancers. Oncol Rep 2008;19:1565-70
71. Osawa S, Terashima Y, Kimura G, et al. Antitumour effects of the angiogenesis inhibitor AGM-1470 on rat urinary bladder tumours induced by N-butyl-N- (4-hydroxybutyl) nitrosamine. BJU Int 1999;83:123-8 (Pubitemid 29151419)
72. Szende B, Juhasz E, Lapis K, et al. Inhibition of two-step urinary bladder carcinogenesis by the somatostatin analogue RC-160. Urol Res 1992;20:383-6
73. Thompson HJ, Becci PJ, Grubbs CJ, et al. Inhibition of urinary bladder cancer by N-(ethyl)-all-trans-retinamide and N-(2-hydroxyethyl)-all-trans- retinamide in rats and mice. Cancer Res 1981;41:933-6 (Pubitemid 11136338)
74. Okajima E, Denda A, Ozono S, et al. Chemopreventive effects of nimesulide, a selective cyclooxygenase-2 inhibitor, on the development of rat urinary bladder carcinomas initiated by N-butyl-N-(4- hydroxybutyl)nitrosamine. Cancer Res 1998;58:3028-31 (Pubitemid 28335083)
75. Yu A, Hashimura T, Nishio Y, et al. Anti-promoting effect of nordihydroguaiaretic acid on N-butyl-N- (4-hydroxybutyl)nitrosamine and sodium saccharin induced rat urinary bladder carcinogenesis. Jpn J Cancer Res 1992;83:944-8
76. Okajima E, Ozono S, Endo T, et al. Chemopreventive efficacy of piroxicam administered alone or in combination with lycopene and beta-carotene on the development of rat urinary bladder carcinoma after N-butyl-N-(4- hydroxybutyl) nitrosamine treatment. Jpn J Cancer Res 1997;88:543-52 (Pubitemid 27348490)
77. Hattori K, Iida K, Joraku A, et al. Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis. BJU Int 2006;97:640-3
78. Okazaki K, Yamagishi M, Son HY, et al. Simultaneous treatment with benzyl isothiocyanate, a strong bladder promoter, inhibits rat urinary bladder carcinogenesis by N-butyl-N-(4- hydroxybutyl)nitrosamine. Nutr Cancer 2002;42:211-16 (Pubitemid 35253671)
79. Masuda C, Wanibuchi H, Sekine K, et al. Chemopreventive effects of bovine lactoferrin on N-butyl-N-(4- hydroxybutyl)nitrosamine-induced rat bladder carcinogenesis. Jpn J Cancer Res 2000;91:582-8 (Pubitemid 30453784)
80. Salim EI, Wanibuchi H, Morimura K, et al. Inhibitory effects of 1,3- diaminopropane, an ornithine decarboxylase inhibitor, on rat two-stage urinary bladder carcinogenesis initiated by N-butyl-N-(4-hydroxybutyl) nitrosamine. Carcinogenesis 2000;21:195-203 (Pubitemid 30098703)
81. Okajima E, Tsutsumi M, Ozono S, et al. Inhibitory effect of tomato juice on rat urinary bladder carcinogenesis after N-butyl-N-(4-hydroxybutyl) nitrosamine initiation. Jpn J Cancer Res 1998;89:22-6 (Pubitemid 28067506)
82. Hirose Y, Tanaka T, Kawamori T, et al. Chemoprevention of urinary bladder carcinogenesis by the natural phenolic compound protocatechuic acid in rats. Carcinogenesis 1995;16:2337-42
83. Zhang X, Jin L, Takenaka I. MVAC chemotherapy-induced apoptosis and p53 alterations in the rat model of bladder cancer. Urology 1998;52:925-31 (Pubitemid 28489737)
84. Parada B, Reis F, Figueiredo A, et al. Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model. BJU Int 2011;107:135-43
85. Babaya K, Takahashi S, Momose H, et al. Effects of single chemotherapeutic agents on development of urinary bladder tumor induced by N-butyl-N-(4- hydroxybutyl) nitrosamine (BBN) in rats. Urol Res 1987;15:329-34 (Pubitemid 18041690)
86. Parada B, Reis F, Cerejo R, et al. Omega-3 fatty acids inhibit tumor growth in a rat model of bladder cancer. Biomed Res Int 2013;2013:368178
87. Parada B, Reis F, Pinto A, et al. Chemopreventive efficacy of atorvastatin against nitrosamine-induced rat bladder cancer: antioxidant, anti-proliferative and anti-inflammatory properties. Int J Mol Sci 2012;13:8482-99
88. Sereno J, Parada B, Reis F, et al. Preventive but not curative efficacy of celecoxib on bladder carcinogenesis in a rat model. Mediators Inflamm 2010;2010:380937
89. Parada B, Sereno J, Reis F, et al. Anti-inflammatory, anti-proliferative and antioxidant profiles of selective cyclooxygenase-2 inhibition as chemoprevention for rat bladder carcinogenesis. Cancer Biol Ther 2009;8:1615-22
90. Chihara Y, Fujimoto K, Miyake M, et al. Antitumor effect of cimetidine via inhibiting angiogenesis factors in N-butyl-N-(4-hydroxybutyl) nitrosamineinduced mouse and rat bladder carcinogenesis. Oncol Rep 2009;22:23-8
91. Ihlaseh SM, de Oliveira ML, Tera'n E, et al. Chemopreventive property of dietary ginger in rat urinary bladder chemical carcinogenesis. World J Urol 2006;24:591-6 (Pubitemid 44782313)
92. Sato D, Matsushima M. Preventive effects of urinary bladder tumors induced by N-butyl-N-(4-hydroxybutyl)- nitrosamine in rat by green tea leaves. Int J Urol 2003;10:160-6 (Pubitemid 36470027)
93. Kawahara M, Matsuhashi T, Yagishita T, et al. Inhibition of N-butyl-N-(4- hydroxybutyl) nitrosamine-induced urinary bladder tumor in rats by alpha-difluoromethylornithine. Hinyokika Kiyo 1987;33:27-30
94. Dornelas CA, Fechine-Jamacaru FV, Albuquerque IL, et al. Angiogenesis inhibition by green propolis and the angiogenic effect of L-lysine on bladder cancer in rats. Acta Cir Bras 2012;27:529-36
95. Takei S, Iseda T, Yokoyama M. Inhibitory effect of clotrimazole on angiogenesis associated with bladder epithelium proliferation in rats. Int J Urol 2003;10:78-85 (Pubitemid 36398914)
96. Wada S, Kinoshita Y, Kamizuru M, et al. A study of antitumor effects of thymosin on rat and mouse urinary bladder carcinoma induced by N-butyl- N-(4-hydroxybutyl)-nitrosamine. Oncol Res 1996;8:139-44 (Pubitemid 26239422)
97. Fujita J, Tokuda H, Ito Y, et al. Therapeutic effect of a retinoid (Ro 10-9359) on rats with bladder tumours induced by N-butyl-N-(4-hydroxybutyl)- nitrosamine upon administration alone or in combination with mitomycin C. Urol Res 1983;11:227-30 (Pubitemid 14249769)
98. Reis LO, Ferreira U, Billis A, et al. Antiangiogenic effects of the superantigen staphylococcal enterotoxin B and Bacillus Calmette-Guerin immunotherapy for non muscle invasive bladder cancer. J Urol 2012;187:438-45
99. Konety BR, Lavelle JP, Pirtskalaishvili G, et al. Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J Urol 2001;165:253-8
100. Kong C, Zhu Y, Sun C, et al. Inhibition of tumor angiogenesis during cisplatin chemotherapy for bladder cancer improves treatment outcome. Urology 2005;65:395-9 (Pubitemid 40248049)
101. Zeng J, Sun Y, Wu K, et al. Chemopreventive and chemotherapeutic effects of intravesical silibinin against bladder cancer by acting on mitochondria. Mol Cancer Ther 2011;10:104-16
102. Ou TT, Wu CH, Hsu JD, et al. Paeonia lactiflora Pall inhibits bladder cancer growth involving phosphorylation of Chk2 in vitro and in vivo. J Ethnopharmacol 2011;135:162-72
103. Holmang S, Cano M, Grenabo L, et al. Effect of indomethacin on N-4-(5-nitro- 2-furyl)-2-thiazolyl] formamide-induced urinary tract carcinogenesis. Carcinogenesis 1995;16:1493-8
104. Vasconcelos-Nobrega C, Pinto-Leite R, Arantes-Rodrigues R, et al. In vivo and in vitro effects of RAD001 on bladder cancer. Urol Oncol 2013;31:1212-21
105. Oliveira PA, Arantes-Rodrigues R, Sousa-Diniz C, et al. The effects of sirolimus on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Res 2009;29:3221-6
106. Vasconcelos-Nobrega C, Colaco A, Santos L, et al. Experimental study of the anticancer effect of gemcitabine combined with sirolimus on chemically induced urothelial lesions. Anticancer Res 2011;31:1637-42
107. Tyagi A, Raina K, Singh RP, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007;6:3248-55
108. Arantes-Rodrigues R, Pinto-Leite R, Ferreira R, et al. Meloxicam in the treatment of in vitro and in vivo models of urinary bladder cancer. Biomed Pharmacother 2013;67:277-84
109. Miyazawa K, Miyamoto S, Suzuki R, et al. Dietary beta-cryptoxanthin inhibits N-butyl-N-(4-hydroxybutyl) nitrosamineinduced urinary bladder carcinogenesis in male ICR mice. Oncol Rep 2007;17:297-304
110. Yang M, Tanaka T, Hirose Y, et al. Chemopreventive effects of diosmin and hesperidin on N-butyl-N-(4- hydroxybutyl)nitrosamine-induced urinary-bladder carcinogenesis in male ICR mice. Int J Cancer 1997;73:719-24 (Pubitemid 127483070)
111. Tanaka T, Morishita Y, Suzui M, et al. Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 1994;15:15-19 (Pubitemid 24121618)
112. Ozawa A, Tanji N, Kikugawa T, et al. Inhibition of bladder tumour growth by histone deacetylase inhibitor. BJU Int 2010;105:1181-6
113. Nishikawa T, Kohjimoto Y, Nishihata M, et al. Synergistic antitumor effects of fleroxacin with 5-fluorouracil in vitro and in vivo for bladder cancer cell lines. Urology 2009;74:1370-6
114. George SK, Tovar-Sepulveda V, Shen SS, et al. Chemoprevention of BBN-induced bladder carcinogenesis by the selective estrogen receptor modulator tamoxifen. Transl Oncol 2013;6:244-55
115. Becci PJ, Thompson HJ, Grubbs CJ, et al. Inhibitory effect of 13-cis-retinoic acid on urinary bladder carcinogenesis induced in C57BL/6 mice by N-butyl- N-(4-hydroxybutyl)-nitrosamine. Cancer Res 1978;38:4463-6 (Pubitemid 9065417)
116. Lubet RA, Huebner K, Fong LY, et al. 4-Hydroxybutyl(butyl) nitrosamineinduced urinary bladder cancers in mice: characterization of FHIT and surviving expression and chemopreventive effects of indomethacin. Carcinogenesis 2005;26:571-8 (Pubitemid 41214146)
117. Rao KV, Detrisac CJ, Steele VE, et al. Differential activity of aspirin, ketoprofen and sulindac as cancer chemopreventive agents in the mouse urinary bladder. Carcinogenesis 1996;17:1435-8 (Pubitemid 26242647)
118. Moon RC, Kelloff GJ, Detrisac CJ, et al. Chemoprevention of OH-BBN-induced bladder cancer in mice by oltipraz, alone and in combination with 4-HPR and DFMO. Anticancer Res 1994;14:5-11 (Pubitemid 24132081)
119. D'Arca D, LeNoir J, Wildemore B, et al. Prevention of urinary bladder cancer in the FHIT knock-out mouse with rofecoxib, a Cox-2 inhibitor. Urol Oncol 2010;28:189-94
120. Chihara Y, Fujimoto K, Miyake M, et al. Antitumor effect of cimetidine via inhibiting angiogenesis factors in Nbutyl- N-(4-hydroxybutyl) nitrosamineinduced mouse and rat bladder carcinogenesis. Oncol Rep 2009;22:23-8
121. Bidinotto LT, Spinardi-Barbisan AL, Rocha NS, et al. Effects of ginger (Zingiber officinale Roscoe) on DNA damage and development of urothelial tumors in a mouse bladder carcinogenesis model. Environ Mol Mutagen 2006;47:624-30 (Pubitemid 44701598)
122. Miyake H, Hara I, Gohji K, et al. Expression of basic fibroblast growth factor is associated with resistance to cisplatin in a human bladder cancer cell line. Cancer Lett 1998;123:121-6 (Pubitemid 28064088)
123. Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammine platinuminduced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73:655-60
124. Sonpavde G, Jian W, Liu H, et al. Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model. Urol Oncol 2009;27:391-9
125. Kassouf W, Luongo T, Brown G, et al. Schedule dependent efficacy of gefitinib and docetaxel for bladder cancer. J Urol 2006;176:787-92 (Pubitemid 43927919)
126. Kamat AM, Karashima T, Davis DW, et al. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 2004;3:279-90 (Pubitemid 39193703)
127. Chiong E, Lee IL, Dadbin A, et al. Effects of mTOR inhibitor everolimus (RAD001) on bladder cancer cells. Clin Cancer Res 2011;17:2863-73
128. Sato K, Yuasa T, Nogawa M, et al. A third-generation bisphosphonate, minodronic acid (YM529), successfully prevented the growth of bladder cancer in vitro and in vivo. Br J Cancer 2006;95:1354-61 (Pubitemid 44760085)
129. Kosugi M, Miyajima A, Kikuchi E, et al. Effect of angiotensin II type 1 receptor antagonist on tumor growth and angiogenesis in a xenograft model of human bladder cancer. Hum Cell 2007;20:1-9 (Pubitemid 46761472)
130. Kosugi M, Miyajima A, Kikuchi E, et al. Angiotensin II type 1 receptor antagonist enhances cis-dichlorodiammine platinuminduced cytotoxicity in mouse xenograft model of bladder cancer. Urology 2009;73:655-60
131. Ma Y, Yu WD, Trump DL, et al. 1,25D3 Enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010;116:3294-303
132. Adhim Z, Matsuoka T, Bito T, et al. In vitro and in vivo inhibitory effect of three COX-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines. Br J Cancer 2011;105:393-402
133. Sun F, Zheng XY, Ye J, et al. Potential anticancer activity of myricetin in human T24 bladder cancer cells both in vitro and in vivo. Nutr Cancer 2012;64:599-606
134. Bai Y, Mao QQ, Qin J, et al. Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells in vitro and inhibits tumor growth in vivo. Cancer Sci 2010;101:488-93
135. Smakman N, Schaap N, Snijckers CM, et al. NS-398, a selective cyclooxygenase-2 inhibitor, reduces experimental bladder carcinoma outgrowth by inhibiting tumor cell proliferation. Urology 2005;66:434-40 (Pubitemid 41138120)
136. Okamoto A, Shirakawa T, Bito T, et al. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of Ecadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology 2008;71:156-60 (Pubitemid 351173283)
137. Mohammed SI, Dhawan D, Abraham S, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther 2006;5:329-36
138. Azuma H, Takahara S, Horie S, et al. Induction of apoptosis in human bladder cancer cells in vitro and in vivo caused by FTY720 treatment. J Urol 2003;169:2372-7 (Pubitemid 36576803)
139. Plissonnier ML, Fauconnet S, Bittard H, et al. The antidiabetic drug ciglitazone induces high-grade bladder cancer cell apoptosis through the up-regulation of TRAIL. PLoS One 2011;6:e28354
140. Singh RP, Tyagi A, Sharma G, et al. Oral silibinin inhibits in vivo human bladder tumor xenograft growth involving down-regulation of survivin. Clin Cancer Res 2008;14:300-8 (Pubitemid 351378006)
141. Yang S, Chen J, Guo Z, et al. Triptolide inhibits the growth and metastasis of solid tumors. Mol Cancer Ther 2003;2:65-72
142. Horinaga M, Fukuyama R, Iida M, et al. Enhanced antitumor effect of coincident intravesical gemcitabine plus BCG therapy in an orthotopic bladder cancer model. Urology 2010;76(5):1267.e1-6
143. Nativ O, Dalal E, Laufer M, et al. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 2004;64:845-8 (Pubitemid 39446086)
144. Yu DS, Lee CF, Hsieh DS, et al. Antitumor effects of recombinant BCG and interleukin-12 DNA vaccines on xenografted murine bladder cancer. Urology 2004;63:596-601
145. Chan ES, Patel AR, Hansel DE, et al. Sunitinib malate provides activity against murine bladder tumor growth and invasion in a preclinical orthotopic model. Urology 2012;80:736.e1-5
146. Swellam T, Miyanaga N, Onozawa M, et al. Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies. Int J Urol 2003;10:213-19 (Pubitemid 36606371)
147. Liu H, Schwartz MJ, Hwang DH, et al. Tumour growth inhibition by an imidazoquinoline is associated with cMyc down-regulation in urothelial cell carcinoma. BJU Int 2008;101:894-901 (Pubitemid 351347734)
148. Ikemoto S, Sugimura K, Kuratukuri K, et al. Antitumor effects of lipoxygenase inhibitors on murine bladder cancer cell line (MBT-2). Anticancer Res 2004;24:733-6 (Pubitemid 38625014)
149. Ikemoto S, Sugimura K, Yoshida N, et al. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 2000;55:951-5 (Pubitemid 30330816)
150. Moon DG, Cheon J, Yoon DH, et al. Allium sativum potentiates suicide gene therapy for murine transitional cell carcinoma. Nutr Cancer 2000;38:98-105 (Pubitemid 32377949)
151. Yang HJ, Yen MC, Lin CC, et al. A combination of the metabolic enzyme inhibitor APO866 and the immune adjuvant L-1-methyl tryptophan induces additive antitumor activity. Exp Biol Med 2010;235:869-76
152. Moltedo B, Faunes F, Haussmann D, et al. Immunotherapeutic effect of Concholepas hemocyanin in the murine bladder cancer model: evidence for conserved antitumor properties among hemocyanins. J Urol 2006;176:2690-5 (Pubitemid 44755063)
153. Kamat AM, Tharakan ST, Sung B, et al. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 2009;69:8958-66
154. Guais A, Baronzio G, Sanders E, et al. Adding a combination of hydroxycitrate and lipoic acid (METABLOC) to chemotherapy improves effectiveness against tumor development: experimental results and case report. Invest New Drugs 2012;30:200-11
155. Schwartz L, Abolhassani M, Guais A, et al. A combination of alpha lipoic acid and calcium hydroxycitrate is efficient against mouse cancer models: preliminary results. Oncol Rep 2010;23:1407-16
156. Lee KE, Iwamura M, Cockett AT. Cortisone inhibition of tumor angiogenesis measured by a quantitative colorimetric assay in mice. Cancer Chemother Pharmacol 1990;26:461-3 (Pubitemid 20333753)
157. Selman SH, Keck RW. A comparative study of the inhibiting effects of mitomycin C and polyphenolic catechins on tumor cell implantation/growth in a rat bladder tumor model. J Urol 2011;186:702-6
158. Abramjuk C, Bueschges M, Schnorr J, et al. Divergent effects of taurolidine as potential antineoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. Oncol Rep 2009;22:409-14
159. Xiao Z, Hanel E, Mak A, et al. Antitumor efficacy of intravesical BCG, gemcitabine, interferon-alpha and interleukin-2 as mono- or combinationtherapy for bladder cancer in an orthotopic tumor model. Clin Med Insights Oncol 2011;5:315-23
160. Bhattacharya A, Li Y, Geng F, et al. The principal urinary metabolite of allyl isothiocyanate, N-acetyl-S-(Nallylthiocarbamoyl) cysteine, inhibits the growth and muscle invasion of bladder cancer. Carcinogenesis 2012;33:394-8
161. Xiao Z, Mak A, Koch K, et al. A molecular complex of bovine milk protein and oleic acid selectively kills cancer cells in vitro and inhibits tumour growth in an orthotopic rat bladder tumour model. BJU Int 2013;112:E201-10
162. Bhattacharya A, Tang L, Li Y, et al. Inhibition of bladder cancer development by allyl isothiocyanate. Carcinogenesis 2010;31:281-6
163. Nativ O, Aronson M, Medalia O, et al. Anti-neoplastic activity of paclitaxel on experimental superficial bladder cancer: in vivo and in vitro studies. Int J Cancer 1997;70:297-301 (Pubitemid 27099598)
164. Brocks CP, Buttner H, Bohle A. Inhibition of tumor implantation by intravesical gemcitabine in a murine model of superficial bladder cancer. J Urol 2005;174:1115-18 (Pubitemid 41140697)
165. Nativ O, Dalal E, Laufer M, et al. Antineoplastic effect of gemcitabine in an animal model of superficial bladder cancer. Urology 2004;64:845-8 (Pubitemid 39446086)
166. Watanabe FT, Chade DC, Reis ST, et al. Curcumin, but not Prima-1, decreased tumor cell proliferation in the syngeneic murine orthotopic bladder tumor model. Clinics (Sao Paulo) 2011;66:2121-4
167. Leite KR, Chade DC, Sanudo A, et al. Effects of curcumin in an orthotopic murine bladder tumor model. Int Braz J Urol 2009;35:599-606
168. Riemensberger J, Bohle A, Brandau S. IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer. Clin Exp Immunol 2002;127:20-6 (Pubitemid 34155453)
169. Hayashi T, Crain B, Corr M, et al. Intravesical Toll-like receptor 7 agonist R-837: optimization of its formulation in an orthotopic mouse model of bladder cancer. Int J Urol 2010;17:483-90
170. Mossberg AK, Hou Y, Svensson M, et al. HAMLET treatment delays bladder cancer development. J Urol 2010;183:1590-7
171. Shen CH, Shee JJ, Wu JY, et al. Combretastatin A-4 inhibits cell growth and metastasis in bladder cancer cells and retards tumour growth in a murine orthotopic bladder tumour model. Br J Pharmacol 2010;160:2008-27
172. Zhou JR, Mukherjee P, Gugger ET, et al. Inhibition of murine bladder tumorigenesis by soy isoflavones via alterations in the cell cycle, apoptosis, and angiogenesis. Cancer Res 1998;58:5231-8 (Pubitemid 28521187)